

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

United States Patent and Trademark  
Office  
(Box PCT)  
Crystal Plaza 2  
Washington, DC 20231  
ÉTATS-UNIS D'AMÉRIQUE

in its capacity as elected Office

Date of mailing (day/month/year)

15 October 1998 (15.10.98)

International application No.

PCT/US98/03355

Applicant's or agent's file reference

17224PCTAP

International filing date (day/month/year)

20 February 1998 (20.02.98)

Priority date (day/month/year)

20 February 1997 (20.02.97)

Applicant

SEFTON, John

1. The designated Office is hereby notified of its election made:



in the demand filed with the International Preliminary Examining Authority on:

17 September 1998 (17.09.98)

in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was

was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Nicola Wolff

Telephone No.: (41-22) 338.83.38

5155021211  
PCT 002 01 01 109/050412

# PCT

## GENERAL POWER OF ATTORNEY

(for several international applications filed under the Patent Cooperation Treaty)

(PCT Rule 90.5)

The undersigned person(s) :

(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

VOET, Martin A., Assistant Secretary  
Allergan Sales, Inc.  
2525 Dupont Drive  
Irvine, CA 92612  
United States of America

hereby appoint(s) the following person as:



agent



common representative

Name and address

(Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

BARAN, Robert J., Registration No. 25,806  
FISHER, Carlos A., Registration No. 36,510  
VOET, Martin A., Registration No. 25,208  
DONOVAN, Stephen, Registration No. 131,928 33,433  
c/o Allergan Sales, Inc.  
2525 Dupont Drive  
Irvine, CA 92612  
United States of America

to represent the undersigned before



all the competent International Authorities



the International Searching Authority only



the International Preliminary Examining Authority only

in connection with any and all international applications filed by the undersigned with the following Office

US and EP


as receiving Office

and to make or receive payments on behalf of the undersigned.

Signature(s) (where there are several persons, each of them must sign; next to each signature, indicate the name of the person signing and the capacity in which the person signs, if such capacity is not obvious from reading this power):

ALLERGAN SALES, INC.

By:



Martin A. Voet, Assistant Secretary

Date:

May 4, 1999

## PATENT COOPERATION T / Y

PCT

NOTIFICATION OF THE RECORDING  
OF A CHANGE(PCT Rule 92bis.1 and  
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

RECEIVED

OCT 19 1998

BARAN, Robert, J.  
Allergan Sales, Inc.  
2525 Dupont Drive  
Irvine, CA 92612  
ETATS-UNIS D'AMERIQUE

LEGAL / PATENTS

Date of mailing (day/month/year) 28 September 1998 (28.09.98)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference 17224PCTAP	
International application No. PCT/US98/03355	International filing date (day/month/year) 20 February 1998 (20.02.98)

## 1. The following indications appeared on record concerning:

☒ the applicant
     
 ☐ the inventor
     
 ☐ the agent
     
 ☐ the common representative

## Name and Address

 VISION PHARMACEUTICALS L.P.  
 2525 Dupont Drive  
 Irvine, CA 92612  
 United States of America

## State of Nationality

US

## State of Residence

US

## Telephone No.

## Facsimile No.

## Teleprinter No.

## 2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:

☐ the person
     
 ☒ the name
     
 ☐ the address
     
 ☐ the nationality
     
 ☐ the residence

## Name and Address

 ALLERGAN SALES, INC.  
 2525 Dupont Drive  
 Irvine, CA 92612  
 United States of America

## State of Nationality

US

## State of Residence

US

## Telephone No.

## Facsimile No.

## Teleprinter No.

## 3. Further observations, if necessary:

**Please note that the change of company name has to be recorded also for the agent's address as indicated in the addressee box at the top of this form.**

## 4. A copy of this notification has been sent to:

☒ the receiving Office
     
 ☐ the designated Offices concerned  
☐ the International Searching Authority
     
 ☐ the elected Offices concerned  
☐ the International Preliminary Examining Authority
     
 ☐ other:

 The International Bureau of WIPO  
 34, chemin des Colombettes  
 1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Maria Victoria CORTIELLO

Telephone No.: (41-22) 338.83.38

# PATENT COOPERATION TREATY

REC'D 01 DEC 1998  
WIPO PCT

## PCT

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 17224PCTAP	<b>FOR FURTHER ACTION</b>		See Notification of Transmittal of International Preliminary Examination Report (PCT/IPEA/416)
International application No. PCT/US98/03355	International filing date (day/month/year) 20/02/1998	Priority date (day/month/year) 20/02/1997	
International Patent Classification (IPC) or national classification and IPC A61K31/57			
Applicant ALLERGAN SALES, INC. et al			

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 4 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 17/09/1998	Date of completion of this report 27.11.98
Name and mailing address of the IPEA/  European Patent Office D-80298 Munich Tel. (+49-89) 2399-0, Tx: 523656 epmu d Fax: (+49-89) 2399-4465	Authorized officer Gore, V  Telephone No. (+49-89) 2399-8590

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US98/03355

## I. Basis of the report

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

### Description, pages:

1-13                      filed with the demand

### Claims, No.:

1-11                      filed with the demand

### Drawings, sheets:

1-2                        filed with the demand

2. The amendments have resulted in the cancellation of:

- ☐ the description,        pages:
- ☐ the claims,            Nos.:
- ☐ the drawings,        sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/US98/03355

---

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

**1. Statement**

Novelty (N)	Yes:	Claims	1-11 (YES)
	No:	Claims	
Inventive step (IS)	Yes:	Claims	1-11 (YES)
	No:	Claims	
Industrial applicability (IA)	Yes:	Claims	1-11 see separate sheet
	No:	Claims	

**2. Citations and explanations**

**see separate sheet**

1. Reference is made to the following document :

D1 : Biological abstracts, vol.31, Philadelphia, US (1980), XP002067727

**Regarding point V**

2. For the assessment of the present claims 1-11 on the question whether they are industrially applicable, no unified criteria exist in the PCT. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.
3. The use of a combination of tazarotene and a corticosteroid for the manufacture of a medicament for treating proliferative skin diseases is not explicitly disclosed in the prior art. Claims 1-11 seem to be novel.
4. D1 discloses that the combination of the aromatic retinoid Ro 10-9359 (orally) with a corticosteroid (triamcinolone acetonid) applied topically is as effective for treating psoriasis as the retinoid alone (in high dosage) but with less side-effects.  
Ro 10-9359, also called Tigason®, is (all E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethyl-2,4,6,8-nonatetranoic acid ethyl ester. Tazarotene is also a retinoid, but of the formula ethyl 6-[2-(4,4)dimethyl-thiochroman-6-yl] ethynyl nicotinate.  
D1 suggests to use a combination of oral Tigason® with topical corticosteroids to treat psoriasis, but it does not disclose or suggest a compound such as tazarotene as an alternative to Tigason® in this combination. Although tazarotene as a single active compound has been approved for the treatment of psoriasis (see page 3 of the application), it does not seem obvious for the person skilled in the art that it would be advantageous to combine it with corticosteroids. It follows that the subject-matter of claims 1-1 appears to involve an inventive step.

# TENT COOPERATION TREATY

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>17224PCTAP</b>	<b>FOR FURTHER ACTION</b> see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. <b>PCT/US 98/ 03355</b>	International filing date (day/month/year) <b>20/02/1998</b>	(Earliest) Priority Date (day/month/year) <b>20/02/1997</b>
Applicant  <b>ALLERGAN et al.</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. ☒ Certain claims were found unsearchable (see Box I).

2. ☐ Unity of invention is lacking (see Box II).

3. ☐ The international application contains disclosure of a nucleotide and/or amino acid sequence listing and the international search was carried out on the basis of the sequence listing

☐ filed with the international application.

☐ furnished by the applicant separately from the international application,

☐ but not accompanied by a statement to the effect that it did not include matter going beyond the disclosure in the international application as filed.

☐ Transcribed by this Authority

4. With regard to the title, ☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this International Search Report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is:

Figure No. \_\_\_\_\_ ☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 98/03355

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 1-11 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/03355

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/57 //(A61K31/57,31:44)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BIOLOGICAL ABSTRACTS, vol. 10, Philadelphia, PA, US; abstract no. 981998, SCHWARTZ E ET AL: "In vivo prevention of corticosteroid-induced skin atrophy by tretinoin in the hairless mouse is accompanied by modulation of collagen, glycosaminoglycans, and fibronectin" XP002067726 see abstract & JOURNAL OF INVESTIGATIVE DERMATOLOGY, 102 (2). 1994. 241-246., --- -/--	1-11



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## ° Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 June 1998

Date of mailing of the international search report

01.07.1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Leherte, C

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/03355

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>BIOLOGICAL ABSTRACTS, vol. 31, Philadelphia, PA, US; abstract no. 16902, VAN DER RHEE H J ET AL: "COMBINED TREATMENT OF PSORIASIS WITH A NEW AROMATIC RETINOID TIGASON IN LOW DOSAGE ORALLY AND TRIAMCINOLONE ACETONIDE CREAM TOPICALLY A DOUBLE-BLIND TRIAL" XP002067727 see abstract &amp; BR J DERMATOL, 102 (2). 1980. 203-212., -----</p>	1-11

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/57 // (A61K 31/57, 31:44)</b>		<b>A1</b>	(11) International Publication Number: <b>WO 98/36753</b>
			(43) International Publication Date: 27 August 1998 (27.08.98)
(21) International Application Number: PCT/US98/03355		<input checked="" type="checkbox"/> (81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(22) International Filing Date: 20 February 1998 (20.02.98)			
(30) Priority Data: 60/039,151 20 February 1997 (20.02.97) US			
(71) Applicant (for all designated States except US): VISION PHARMACEUTICALS L.P. [US/US]; 2525 Dupont Drive, Irvine, CA 92612 (US).			
(72) Inventor; and (75) Inventor/Applicant (for US only): SEFTON, John [US/US]; P.O. Box 714, Trabuco Canyon, CA 92678 (US).			
(74) Agents: BARAN, Robert, J. et al.; Vision Pharmaceuticals L.P., 2525 Dupont Drive, Irvine, CA 92612 (US).			
(54) Title: TAZAROTENE AND CORTICOSTEROID TREATMENT FOR PSORIASIS ✓			
(57) Abstract  The present invention provides a method for treating proliferative skin diseases comprising the administration of an effective amount of tazarotene and an effective amount of a corticosteroid. This invention is especially useful for treating psoriasis.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## TAZAROTENE AND CORTICOSTEROID TREATMENT FOR PSORIASIS

### 5 CROSS REFERENCE TO RELATED APPLICATIONS

This patent application claims priority from Provisional Patent Application 60/03915 filed on February 20, 1997.

### 10 BACKGROUND OF THE INVENTION

#### 1. FIELD OF THE INVENTION

15 This invention relates to pharmaceutical compositions for application to the skin and to a method for the treatment of proliferating skin diseases. The composition may be applied topically. The treatment can be either therapeutic or prophylactic.

#### 20 2. DESCRIPTION OF RELATED ART

Proliferative skin diseases are widespread throughout the world and afflict millions of humans and their domesticated animals. This invention provides a method for treatment of such diseases. As used hereinafter in this specification and in the claims, the expression "proliferative skin  
25 diseases" means benign and malignant proliferative skin diseases which are characterized by accelerated cell division in the epidermis, dermis or appendages thereto, associated with incomplete tissue differentiation. Such diseases include: psoriasis, atopic dermatitis, non-specific dermatitis, primary irritant contact dermatitis, allergic contact dermatitis, basal and  
30 squamous cell carcinomas of the skin, lamellar ichthyosis, epidermolytic hyperkeratosis, premalignant sun-induced keratosis, non-malignant

keratosis, acne, and seborrhic dermatitis in humans and atopic dermatitis in domesticated animals.

Heretofore, proliferative skin diseases have been generally accepted by mankind as an ongoing evil having degrees of severity variable with  
5 inherited skin traits and external factors but always have been recognized as unsightly, painful, morbid diseases. Over the history of mankind innumerable medicines and treatments have been proposed, tried and used with varying degrees of success.

Treatments which are prescribed and used for the treatment of  
10 proliferative skin diseases include the following:

- (1) topical applications, e.g. coal tar derivatives, 5-fluorouracil, vitamin A acid, glucocorticoids in high dosage, bath oils and non-specific emollient creams and ointments;
- 15 (2) systemic administration, e.g. glucocorticoids and classic anti-cancer agents, for example, methothrexate, hydroxyurea, azaribine, cyclophosphamide; and
- (3) physical modalities, e.g. ultra violet light, x-radiation, and, in severe cases, surgery.

20 While these treatments provide, in certain cases some remission of the original symptoms, each treatment suffers some defect, for example, temporary and incomplete mitigation of symptoms, rapid re-occurrence of the disease when mitigation is terminated, serious and sometimes irreversible damage (atrophy) resulting from the topical application for  
25 extended times of glucocorticoids, acute bone marrow suppression, cirrhosis of the liver resulting from the protracted use of methothrexate which may lead to death of the patient, and the causation of cancer by the application of anti-cancer drugs, x-radiation, or ultra violet rays.

Recently, a new compound has been approved by the Food and Drug Administration for the treatment of psoriasis and acne. Tazarotene. Tazarotene is available as Tazorac® 0.1% and Tazorac® 0.05% topical gel from Allergan, Inc. of Irvine, California.

5

#### BRIEF SUMMARY OF THE INVENTION

The present invention relates to a method of treating psoriasis in humans with tazarotene, preferably a gel comprising 0.1%, tazarotene by weight, and a corticosteroid, preferably a cream. The tazarotene gel may be administered once daily in the evening and the corticosteroid cream may be administered to the subject once daily in the morning, or the gel and cream may be administered on alternate days. The tazarotene gel is disclosed in U.S. patent Application Serial no. 623,184, which is entitled "Stable Gel Formulation for Topical Treatment of Skin Conditions", which was filed on March 28, 1996, in the name of Prakash Charu and is hereby incorporated by reference in its entirety.

In one aspect of the invention, the corticosteroid may be Synalar® cream (0.01% fluocinolone acetonide), Elocon® cream (0.1% mometasone furoate) or Lidex® cream (0.05% fluocinonide), i.e. a low-potency, mid-potency and high-potency corticosteroid, respectively.

In another aspect of the invention, the corticosteroid may be fluocinonide 0.05% ointment, Lidex®, a high potency steroid, mometasone furoate 0.1% ointment, Elocon®, a high potency steroid, diflorasone diacetate 0.05% ointment, Maxiflor®, a high potency steroid, fluticasone propionate 0.005% ointment, Cultivate®, a mid-potency steroid, betamethasone dipropionate 0.05% cream, Diprosone®, a mid-potency steroid, diflorasone diacetate 0.05% cream, Maxiflor®, a mid-



potency steroid, clobetasol propionate 0.05% ointment, Temovate®, a super-potency steroid, betamethasone valerate 0.1% lotion, Valisone®, a mid-potency steroid.

## 5 BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graph comparing the reduction in plaque elevation over a 12 week treatment period with tazarotene in combination with placebo, high-potency corticosteroid, mid-potency corticosteroid and low-potency  
10 corticosteroid.

Figure 2 shows the treatment success with the combination therapies of Figure 1.

## DETAILED DESCRIPTION OF THE INVENTION

15

In accordance with this invention it has been found that proliferative skin diseases are alleviated, that is, the symptoms of the disease are noticeably improved or become undetectable, by the treatment of the afflicted patient, or animal, with the pharmaceutical compounds described  
20 in detail, hereinbelow.

For the purposes of this specification and the claims, a proliferative skin disease is alleviated when there is a noticeable decrease in the thickness of a lesion to palpation, with or without residual redness, or residual slightly dilated blood vessels or residual hyper- or hypo-  
25 pigmentation. For purposes of this invention and the claims hereof, psoriasis is alleviated when a scale-free psoriasis lesion is noticeably decreased in thickness, or noticeably but incompletely cleared or completely cleared.

The compositions utilized in the method of this invention may be applied topically.

The term "topical" as employed herein relates to the use of the active ingredient incorporated in a suitable pharmaceutical carrier, and applied at the site of the disease for exertion of local action. Accordingly, such topical compositions include those pharmaceutical forms in which the compound is applied externally by direct contact with the skin surface to be treated. Conventional pharmaceutical forms for this purpose include ointments, lotions, pastes, jellies, sprays, aerosols, bath oils and the like. The term "ointment" embraces formulations (including creams) having oleaginous, absorption, water-soluble and emulsion-type bases, e.g., petroleum, lanolin, polyethylene glycols, as well as mixtures thereof. Topical application with occlusion of an area larger than the medicated area may produce improved results relative to non-occluded topical applications.

The percentage by w/w of the active ingredient, i.e. the corticosteroid herein utilized ranges from about 0.001% to about 1% of the pharmaceutical preparation, preferably from about 0.005% to about 0.1%, by weight.

The percentage by w/w of the active ingredient, i.e. tazarotene herein utilized ranges from about 0.01% to about 15% of the pharmaceutical preparation, preferably from about 0.1% to about 2% and in these preparations the aforesaid pharmaceutical carrier for topical application constitutes a major amount of the said preparation.


Preferably tazarotene is utilized as a stable gel formulation for topical treatment of skin conditions in humans, said stable gel formulation comprising: Ethyl-6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate in a plurality of nonaqueous vehicles for both solubilizing tazarotene and forming a gel therewith, said nonaqueous vehicles enabling topical application of the gel to a skin condition, said plurality of vehicles each

6

being present in amounts, and in combination, to control release of tazarotene from the gel to the skin conditions. In the tazarotene formulation the vehicles are present in amounts selected to produce maximum release of the active agent, i.e. tazarotene, from the gel when all the vehicles are present therein. Preferably the formulation comprises three vehicles and more preferably the formulation comprises three vehicles which are used to both solubilize the active agent and form a gel.

The formulation preferably comprises the three vehicles, e.g. Polysorbate 40, Poloxamer 407 and Hexylene glycol. Polysorbate 40 is

10



wherein the Sum of  $w$ ,  $x$ ,  $y$ , and  $z$  is 20 and  $R$  is  $(\text{C}_{15}\text{H}_{31})\text{COO}$  and Poloxamer 407 is  $\text{HO}(\text{C}_2\text{H}_4\text{O})_a(\text{C}_3\text{H}_6\text{O})_b(\text{C}_2\text{H}_4\text{O})_a\text{H}$  having the following properties.

15

## USAN for Poloxamers

5	Physical Form	Average Molecular Weight	Average Values		BASF Corp. Brand Name
			a	b	
<hr/>					
	Poloxamer				
10					Pluronic
	124	Liquid	2090 to 2360	12 20	L 44
	188	Solid	7680 to 9510	80 27	F 68
	237	Solid	6840 to 8830	64 37	F 87
	338	Solid	12700 to 17400	141 44	F 108
15	407	Solid	9840 to 14600	101 56	F 127

More preferably, tazarotene is utilized as a stable gel formulation for topical treatment of psoriasis comprising an effective amount of Ethyl-6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate in a pharmaceutical

20 carrier comprising:

- (a) water;
- (b) edetate disodium;
- (c) ascorbic acid;
- (d) Carbomer 934P;
- 25 (e) Poloxamer 407;
- (f) polyethylene glycol;
- (g) Polysorbate 40;
- (h) hexylene glycol;
- (i) butylated hydroxytoluene;
- 30 (j) butylated hydroxyanisole;

- (k) benzyl alcohol; and
- (l) tromethamine.

The tazarotene formulation may comprise Polysorbate 40 in an amount up to about 0.4% by weight, Poloxamer 407 in an amount up to about 0.4% by weight, and hexylene glycol in an amount up to about 2% by weight or more preferably Polysorbate 40, in an amount of about 0.32% by weight, Poloxamer 407 in an amount of about 0.18% by weight, and hexylene glycol in an amount of about 2% by weight.

Most preferably, the tazarotene formulation comprises:

	INGREDIENT	FUNCTION	CONCENTRATION %W/W
15	tazarotene	Drug	0.1
	purified water	Excipient	49.25
	Edetate Disodium	Stabilizer	0.05
	Ascorbic acid	Stabilizer	0.05
	Carbomer 934P <sup>1</sup>	Thickening	1.25
20		agent	
	Poloxamer 407	Surfactant	0.2
	PEG-400	Co-solvent	45.0
	Polysorbate 40	Surfactant	0.2
	Hexylene glycol	Co-solvent	2.0
25	Butylated	Stabilizer	0.05
	hydroxytoluene		
	Butylated	Stabilizer	0.05
	hydroxyanisole		
	Benzyl alcohol	Preservative	1.0
30	Triethanolamine/ Tromethamine	Neutralizer	0.8

<sup>1</sup>Carbomer 934P [1975]. NF. The viscosity of a neutralized 0.5 percent aqueous dispersion of Carbomer 934P is between 29,400 and 39,400 centipoises. (1) Polymer of 2-propenoic acid, cross-linked with allyl ethers of sucrose or pentaerythritol; (2) Polymer of acrylic acid, cross-linked with allyl ethers of sucrose or pentaerythritol. Molecular weight is approximately 3,000,000.

The tazarotene formulation and the corticosteroid formulation, each, will be applied, topically, in an amount to achieve the maximum effect on alleviating the proliferative skin disease symptoms without causing an adverse reaction. Selection of such an amount of either formulation is well within the skill of the art.

5        Preferably, the tazarotene formulation is utilized to provide from about 0.5 to about 5 mg of tazarotene per  $\text{cm}^2$  of affected skin, more preferably from about 1 to about 3  $\text{mg}/\text{cm}^2$ , e.g. 2  $\text{mg}/\text{cm}^2$ .

10        The method of this invention also employs a corticosteroid. The expression "corticosteroid" refers to a naturally occurring product of the adrenal cortex, or a synthetic analog thereof possessing anti-inflammatory activity and minimal or no mineralocorticoid activity or sex steroid activity. The corticosteroids include glucocorticoids. Of the natural glucocorticoids, one may use for example, hydrocortisone or the synthetic glucocorticoids such as methyl prednisolone acetate (Prednisone) or triamcinolone for topical therapy. The corticosteroids are  
15        preferably employed in amounts of from 0.5 to 5 mg per  $\text{cm}^2$  of affected skin, more preferably from about 1 to 3  $\text{mg}/\text{cm}^2$ , e.g. 2  $\text{mg}/\text{cm}^2$ .

20        The treatment period may be 12 weeks with a 4 week follow-up period. The subjects are evaluated for plaque elevation, scaling and erythema with a successful treatment defined as about 50% improvement or better. During the treatment period, tazarotene in combination with the mid- or high-potency corticosteroid produced significantly better results than treatment with tazarotene in combination with placebo in reducing plaque elevation, scaling, erythema and overall severity. During the 4 week post-treatment period, the results with  
25        tazarotene plus mid- or high-potency corticosteroid were equal to or better than tazarotene plus placebo or tazarotene plus low-potency corticosteroid.

      The most common adverse events resulting from the treatment were burning, pruritus and erythema; however there was a lower incidence of such adverse events in patients treated with tazarotene plus the medium- or high-potency corticosteroid.

Thus, treating psoriasis in humans with a combination of tazarotene and a mid-potency or high-potency corticosteroid is more effective than a combination of tazarotene and low-potency or placebo and results in a lower incidence of adverse events such as burning pruritis and erythema.

5       The invention is further illustrated by the following examples which are illustrative of various aspects of the invention, and are not intended as limiting the scope of the invention as defined by the appended claims.

### EXAMPLE 1

10

The study reported here utilizes a combination regimen that alternates between tazarotene 0.1% gel and a corticosteroid or placebo cream every evening. The aim of the study was to determine whether such alternating therapy may offer clinical benefits by maximizing the therapeutic benefits of both drugs, while also  
15       minimizing corticosteroid use and thus reducing the potential for adverse corticosteroid-induced effects.

This study was a multicenter, investigator-masked, parallel-group study, enrolling 398 patients with stable plaque psoriasis. Topical applications of tazarotene 0.1% gel, were administered every other evening, and one of the  
20       following creams administered on alternate evenings): placebo; low-potency corticosteroid (hydrocortisone acetate 1%); medium-potency corticosteroid (alclometasone dipropionate 0.05%); or high-potency corticosteroid (betamethasone valerate 0.1%).

The study required a 12-week treatment period plus a 4-week follow-up  
25       phase. The patient demographics included 388 patients (231 male and 157 female) with evaluable data, mean age of 46.7 years (range: 21-88 years) and a mean duration of psoriasis of 17.39 years.

All treatment groups achieved clinically significant reductions in plaque elevation at all treatment and post-treatment visits, with the tazarotene/high-  
30       potency combination taz/high group achieving consistently greater reductions than

the other treatments throughout the study. At week 4, these reductions were significantly greater than those in all the other treatment groups. The taz/high also achieved clinically significant reductions in plaque elevation more rapidly than the other treatments, i.e. in two weeks compared with four weeks in all the other groups. (See the results set forth in Figure 1.)

Treatment success was defined as a moderate, marked, almost clear or completely cleared response ( $\geq 50\%$  global clinical improvement). All tazarotene/corticosteroid treatment groups achieved treatment success rates of  $> 50\%$  within 4 weeks. However, the taz/high combination achieved significantly greater treatment success rates than the tazarotene/placebo (taz/plac) and tazarotene/medium-potency corticosteroid (taz/med) combinations throughout the 12-week treatment period. Peak treatment success rates ranged from 56% (for patients treated with taz/plac at Week 8) to 77% (for taz/high at Week 8).

During the 4-week follow-up period, all groups retained  $\geq 60\%$  global clinical improvements in psoriasis, with treatment success rates ranging from 60% (for taz/med) to 75% (for taz/high) at study Week 16. These improvements were statistically and clinically significant compared with the pretreatment levels and there were no significant differences between the groups at the end of the follow-up period. (See Figure 2.)

Week 12, the probability of patients being considered a treatment success at any study visit was 77% in the taz/high group. In the other groups the treatment success was 56 to 61%.

The taz/high combination also achieved initial treatment success significantly faster than any of the other combinations. The median time to treatment success was 2 weeks in the taz/high group, compared with 4 weeks in each of the other groups.

All treatment groups achieved clinically significant reductions in scaling during the treatment period, and the taz/high combination was consistently the most efficacious treatment throughout the 12-week treatment period. The reductions in



scaling achieved in all groups by the end of the treatment period were generally maintained during the 4-week follow up period.

All treatment groups achieved statistically significant reductions in erythema during the treatment period and, once again, the taz/high combination was the most efficacious treatment. During the follow-up period, all groups retained significant reductions in erythema compared with baseline levels, and these reductions were clinically significant in the taz/high, taz/med, and taz/plac groups.

The overall incidence of adverse events that were possibly, probably or definitely treatment-related decreased with increased corticosteroid potency, falling from 42% in the taz/plac group, to 36%, 32% and 31% in the tazarotene/low-potency corticosteroid (taz/low), taz/med, and taz/high groups, respectively. (See Table II, below.)

**Table II. Overall incidence of adverse events**

	Patients (%)			
	Taz/plac	Taz/low	Taz/med	Taz/high
Pruritus	15	19	16	8
Erythema	12	7	6	6
Irritation	8	9	5	4
Burning	6	4	4	8

In view of the above Example, the following conclusions may be drawn. Alternate-day treatment with tazarotene 0.1% gel and the high potency corticosteroid cream was consistently more effective than the other three regimens in reducing plaque elevation, scaling and erythema. Patients in the tazarotene plus high-potency corticosteroid group also achieved significantly higher treatment

success rates ( $\geq$  50% global clinical improvement, and achieved treatment success faster, than patients in the other groups. Treatment-related adverse events comprised mainly mild to moderate local irritation including pruritus, erythema and burning skin. The incidence of treatment-related adverse events decreased as the  
5 potency of the corticosteroid cream used increased.

### EXAMPLE 2

The study of Example 1 is substantially repeated with fluocinolone  
10 acetonide 0.01% cream (low-potency), mometasone furoate 0.1% cream (mid-potency) and fluocinonide 0.05% cream (high-potency) used as the corticosteroids. In this study tazarotene 0.1% gel in combination with a mid-potency or high-potency corticosteroid, when compared with tazarotene plus placebo cream, was associated with significantly higher treatment success rates, significantly greater  
15 reductions in scaling, erythema, and overall lesional severity, with a decreased incidence of adverse events. The corticosteroids are Synalar® cream, Elocon® cream and Lidex® cream, respectively.

While particular embodiments of the invention have been described, it will be understood of course that the invention is not limited thereto since many obvious  
20 modifications can be made and it is intended to include within this invention any such modifications as will fall within the scope of the appended claims.

Having now described the invention, I claim.

1. A method for treating proliferative skin diseases comprising the administration of an effective amount of tazarotene and an effective amount of a corticosteroid.

5

2. The method of claim 1 wherein said corticosteroid is selected from the group consisting of fluocinolone acetonide, mometasone furoate, fluocinonide, diflorasone diacetate, fluticasone propionate, betamethasone dipropionate, clobetasol propionate, betamethasone valerate.

10

3. The method of claim 1 wherein tazarotene is applied as a 0.1% gel.

4. The method of claim 1 wherein said corticosteroid is a mid- or high-potency corticosteroid.

15

5. The method of claim 4 wherein said corticosteroid is selected from the group consisting of mometasone furoate and fluocinolone acetonide.

6. A method for treating psoriasis in a human subject by topically applying to the psoriatic skin of said subject an effective amount of tazarotene and an effective amount of a corticosteroid.

20

7. The method of claim 6 wherein tazarotene is applied as a 0.1% gel.


25


8. The method of claim 7 wherein said corticosteroid is a cream.

9. The method of claim 8 wherein said corticosteroid is a mid- or high-potency corticosteroid.

10. The method of claim 9 wherein said corticosteroid is selected from the group consisting of mometasone furoate and fluocinolone.

11. The method of claim 6 wherein tazarotene is administered once  
5 daily in the evening and the corticosteroid is administered once daily in the morning.

FIG. 1.



\*  $P < 0.05$  VS TAZ/PLAC AND TAZ/MED

†  $P < 0.05$  VS TAZ/LOW

FIG. 2.

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 98/03355

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/57 //(A61K31/57,31:44)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>BIOLOGICAL ABSTRACTS, vol. 10, Philadelphia, PA, US; abstract no. 981998, SCHWARTZ E ET AL: "In vivo prevention of corticosteroid-induced skin atrophy by tretinoin in the hairless mouse is accompanied by modulation of collagen, glycosaminoglycans, and fibronectin" XP002067726 see abstract &amp; JOURNAL OF INVESTIGATIVE DERMATOLOGY, 102 (2). 1994. 241-246., --- -/--</p>	1-11

☒ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

### \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

11 June 1998

Date of mailing of the international search report

01. 07. 1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Leherte, C

# INTERNATIONAL SEARCH REPORT

Inten. Appl. Application No

PCT/US 98/03355

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>BIOLOGICAL ABSTRACTS, vol. 31,  Philadelphia, PA, US;  abstract no. 16902,  VAN DER RHEE H J ET AL: "COMBINED  TREATMENT OF PSORIASIS WITH A NEW AROMATIC  RETINOID TIGASON IN LOW DOSAGE ORALLY AND  TRIAMCINOLONE ACETONIDE CREAM TOPICALLY A  DOUBLE-BLIND TRIAL"  XP002067727  see abstract  &amp; BR J DERMATOL, 102 (2). 1980. 203-212.,  -----</p>	1-11



# INTERNATIONAL SEARCH REPORT

Int. application No.  
PCT/US 98/03355

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 1-11 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.